The short version of heptapeptide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-01 and is reviewed periodically as new material appears.
Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | ~813.9 Da (free heptapeptide) | N-acetylated form is about 42 Da heavier |
| Residue count | 7 (heptapeptide) | Four residues from ACTH(4-10), three added |
| Appearance | White to off-white powder | Usually supplied lyophilized |
| Solubility class | Freely soluble in water | Also dissolves in DMSO and polar organic solvents |
| Related parent fragment | ACTH(4-10) | Parent motif is Met-Glu-His-Phe |
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
=== German reunification === West German chancellor Helmut Kohl's proposal of a Ten Point Plan on 28 November 1989—a graduated progression from confederation to full federation—moved the German question from a mere platitude to actual politics almost overnight, and the storm of international criticism it provoked was the price of that shift. Gorbachev's opposition, Thatcher's criticism, and French president François Mitterrand's vacillation notwithstanding, Kohl pushed for immediate unification once Dresden crowds took up chanting his name that December; unlike their more cautious political elites, ordinary people in the neighboring countries mostly favored German self-determination. This proposal presented a special dilemma for Gorbachev, since a "divided Germany" had been central to Soviet security strategy since the Stalin era. The resulting Two-Plus-Four negotiations—originally conceived by the U.S. State Department as a "four-plus-two" framework joining the wartime Allies with the two German states, then inverted to acknowledge German sensitivities—translated the East German electorate's March 1990 mandate into an accepted international settlement. In return, Kohl accepted the Oder–Neisse line as Germany's permanent eastern frontier in exchange for keeping reparations off the table, while American pressure and West German aid persuaded Gorbachev to permit a reunified Germany to remain in NATO. Then U.S. Secretary of State James Baker assured Gorbachev on 9 February 1990 that NATO would not expand eastward.
Organizations were started in many countries, and these grew rapidly in membership, most notable among them being the Royal Society for the Protection of Birds (RSPB) in Britain and the Audubon Society in the US, which started in 1885. Both these organizations were started with the primary objective of conservation. The RSPB, born in 1889, grew from a small Croydon-based group of women, including Eliza Phillips, Etta Lemon, Catherine Hall and Hannah Poland. Calling themselves the "Fur, Fin, and Feather Folk", the group met regularly and took a pledge "to refrain from wearing the feathers of any birds not killed for the purpose of food, the ostrich only exempted." The organization did not allow men as members initially, avenging a policy of the British Ornithologists' Union to keep out women. Unlike the RSPB, which was primarily conservation oriented, the British Trust for Ornithology was started in 1933 with the aim of advancing ornithological research. Members were often involved in collaborative ornithological projects. These projects have resulted in atlases which detail the distribution of bird species across Britain. In Canada, citizen scientist Elsie Cassels studied migratory birds and was involved in establishing Gaetz Lakes bird sanctuary. In the United States, the Breeding Bird Surveys, conducted by the United States Geological Survey, have also produced atlases with information on breeding densities and changes in the density and distribution over time. Other volunteer collaborative ornithology projects were subsequently established in other parts of the world.
===== MeSH D08.811.277.352 – esterases (EC 3.1) ===== MeSH D08.811.277.352.100 – carboxylic-ester hydrolases MeSH D08.811.277.352.100.050 – acetylesterase MeSH D08.811.277.352.100.100 – carboxylesterase MeSH D08.811.277.352.100.150 – cholesterol esterase MeSH D08.811.277.352.100.170 – cholinesterases MeSH D08.811.277.352.100.170.176 – acetylcholinesterase MeSH D08.811.277.352.100.170.250 – butyrylcholinesterase MeSH D08.811.277.352.100.170.710 – pseudocholinesterase MeSH D08.811.277.352.100.220 – dehydroascorbatase MeSH D08.811.277.352.100.400 – lipase MeSH D08.811.277.352.100.400.745 – pancrelipase MeSH D08.811.277.352.100.430 – lipoprotein lipase MeSH D08.811.277.352.100.500 – monoacylglycerol lipases MeSH D08.811.277.352.100.550 – naphthol as d esterase MeSH D08.811.277.352.100.680 – phospholipases MeSH D08.811.277.352.100.680.510 – lysophospholipase MeSH D08.811.277.352.100.680.750 – phospholipases a MeSH D08.811.277.352.100.680.750.500 – 1-alkyl-2-acetylglycerophosphocholine esterase MeSH D08.811.277.352.335 – deoxyribonucleases MeSH D08.811.277.352.335.350 – endodeoxyribonucleases MeSH D08.811.277.352.335.350.025 – aspergillus nuclease s1 MeSH D08.811.277.352.335.350.137 – deoxyribonuclease (pyrimidine dimer) MeSH D08.811.277.352.335.350.250 – deoxyribonuclease i MeSH D08.811.277.352.335.350.250.900 – streptodornase and streptokinase MeSH D08.811.277.352.335.350.275 – deoxyribonuclease iv (phage t4-induced) MeSH D08.811.277.352.335.350.300 – dna restriction enzymes MeSH D08.811.277.352.335.350.300.250 – deoxyribonucleases, type i site-specific MeSH D08.811.277.352.335.350.300.260 – deoxyribonucleases, type ii site-specific MeSH D08.811.277.352.335.350.300.260.240 – deoxyribonuclease bamhi MeSH D08.811.277.352.335.350.300.260.250 – deoxyribonuclease ecori MeSH D08.811.277.352.335.350.300.260.260 – deoxyribonuclease hindiii MeSH D08.811.277.352.335.350.300.260.300 – deoxyribonuclease hpaii MeSH D08.811.277.352.335.350.300.270 – deoxyribonucleases, type iii site-specific MeSH D08.811.277.352.335.350.400 – holliday junction resolvases MeSH D08.811.277.352.335.350.500 – micrococcal nuclease MeSH D08.811.277.352.335.375 – exodeoxyribonucleases MeSH D08.811.277.352.335.375.750 – exodeoxyribonuclease V MeSH D08.811.277.352.355 – endonucleases MeSH D08.811.277.352.355.325 – endodeoxyribonucleases MeSH D08.811.277.352.355.325.025 – aspergillus nuclease s1 MeSH D08.811.277.352.355.325.300 – dna restriction enzymes MeSH D08.811.277.352.355.325.300.250 – deoxyribonucleases, type i site-specific MeSH D08.811.277.352.355.325.300.260 – deoxyribonucleases, type ii site-specific MeSH D08.811.277.352.355.325.300.260.240 – deoxyribonuclease bamhi MeSH D08.811.277.352.355.325.300.260.250 – deoxyribonuclease ecori MeSH D08.811.277.352.355.325.300.260.260 – deoxyribonuclease hindiii MeSH D08.811.277.352.355.325.300.260.300 – deoxyribonuclease hpaii MeSH D08.811.277.352.355.325.300.270 – deoxyribonucleases, type iii site-specific MeSH D08.811.277.352.355.325.350 – flap endonucleases MeSH D08.811.277.352.355.325.400 – holliday junction resolvases MeSH D08.811.277.352.355.325.500 – micrococcal nuclease MeSH D08.811.277.352.355.350 – endoribonucleases MeSH D08.811.277.352.355.350.025 – aspergillus nuclease s1 MeSH D08.811.277.352.355.350.500 – micrococcal nuclease MeSH D08.811.277.352.355.350.700 – ribonuclease h, calf thymus MeSH D08.811.277.352.355.350.715 – ribonuclease, pancreatic MeSH D08.811.277.352.355.350.725 – ribonuclease t1 MeSH D08.811.277.352.355.350.810 – RNA-induced silencing complex MeSH D08.811.277.352.365 – exonucleases MeSH D08.811.277.352.365.290 – exodeoxyribonucleases MeSH D08.811.277.352.365.300 – exoribonucleases MeSH D08.811.277.352.640 – phosphoric diester hydrolases MeSH D08.811.277.352.640.050 – annexin A3 MeSH D08.811.277.352.640.125 – 3',5'-cyclic-GMP phosphodiesterase MeSH D08.811.277.352.640.150 – 3',5'-cyclic-nucleotide phosphodiesterase MeSH D08.811.277.352.640.160 – 2',3'-cyclic-nucleotide phosphodiesterases MeSH D08.811.277.352.640.295 – glycerophosphoinositol inositolphosphodiesterase MeSH D08.811.277.352.640.430 – phosphodiesterase i MeSH D08.811.277.352.640.700 – phospholipases MeSH D08.811.277.352.640.700.700 – phospholipase c MeSH D08.811.277.352.640.700.700.500 – phosphatidylinositol diacylglycerol-lyase MeSH D08.811.277.352.640.700.700.750 – phospholipase c gamma MeSH D08.811.277.352.640.700.710 – phospholipase d MeSH D08.811.277.352.640.750 – sphingomyelin phosphodiesterase MeSH D08.811.277.352.650 – phosphoric monoester hydrolases MeSH D08.811.277.352.650.025 – acid phosphatase MeSH D08.811.277.352.650.035 – alkaline phosphatase MeSH D08.811.277.352.650.200 – fructose-bisphosphatase MeSH D08.811.277.352.650.225 – glucose-6-phosphatase MeSH D08.811.277.352.650.300 – histidinol-phosphatase MeSH D08.811.277.352.650.575 – 4-nitrophenylphosphatase MeSH D08.811.277.352.650.600 – nucleotidases MeSH D08.811.277.352.650.600.600 – 5'-nucleotidase MeSH D08.811.277.352.650.620 – phosphatidate phosphatase MeSH D08.811.277.352.650.622 – phosphofructokinase-2 MeSH D08.811.277.352.650.625 – phosphoprotein phosphatase MeSH D08.811.277.352.650.625.150 – calcineurin MeSH D08.811.277.352.650.625.300 – glycogen-synthase-d phosphatase MeSH D08.811.277.352.650.625.475 – myosin light-chain phosphatase MeSH D08.811.277.352.650.625.650 – phosphorylase phosphatase MeSH D08.811.277.352.650.625.700 – protein-tyrosine-phosphatase MeSH D08.811.277.352.650.625.700.150 – antigens, cd45 MeSH D08.811.277.352.650.625.700.200 – cdc25 phosphatase MeSH D08.811.277.352.650.625.725 – pyruvate dehydrogenase (lipoamide)-phosphatase MeSH D08.811.277.352.650.700 – 6-phytase MeSH D08.811.277.352.650.850 – pten phosphohydrolase MeSH D08.811.277.352.660 – phosphoric triester hydrolases MeSH D08.811.277.352.660.500 – aryldialkylphosphatase MeSH D08.811.277.352.700 – ribonucleases MeSH D08.811.277.352.700.350 – endoribonucleases MeSH D08.811.277.352.700.350.025 – aspergillus nuclease s1 MeSH D08.811.277.352.700.350.262 – eosinophil cationic protein MeSH D08.811.277.352.700.350.381 – eosinophil-derived neurotoxin MeSH D08.811.277.352.700.350.500 – micrococcal nuclease MeSH D08.811.277.352.700.350.700 – ribonuclease h, calf thymus MeSH D08.811.277.352.700.350.707 – ribonuclease iii MeSH D08.811.277.352.700.350.711 – ribonuclease p MeSH D08.811.277.352.700.350.715 – ribonuclease, pancreatic MeSH D08.811.277.352.700.350.725 – ribonuclease t1 MeSH D08.811.277.352.700.350.810 – RNA-induced silencing complex MeSH D08.811.277.352.700.375 – exoribonucleases MeSH D08.811.277.352.827 – sulfatases MeSH D08.811.277.352.827.070 – arylsulfatases MeSH D08.811.277.352.827.070.060 – n-acetylgalactosamine-4-sulfatase MeSH D08.811.277.352.827.070.250 – cerebroside-sulfatase MeSH D08.811.277.352.827.070.625 – steryl-sulfatase MeSH D08.811.277.352.827.180 – chondroitinases and chondroitin lyases MeSH D08.811.277.352.827.180.175 – chondroitinsulfatases MeSH D08.811.277.352.827.180.175.060 – n-acetylgalactosamine-4-sulfatase MeSH D08.811.277.352.827.180.175.275 – chondro-4-sulfatase MeSH D08.811.277.352.827.500 – iduronate sulfatase MeSH D08.811.277.352.897 – thiolester hydrolases MeSH D08.811.277.352.897.075 – acetyl-CoA hydrolase MeSH D08.811.277.352.897.700 – palmitoyl-coa hydrolase MeSH D08.811.277.352.897.850 – ubiquitin thiolesterase
=== Angle restraints === In addition to distance restraints, restraints on the torsion angles of the chemical bonds, typically the psi and phi angles, can be generated. One approach is to use the Karplus equation, to generate angle restraints from coupling constants. Another approach uses the chemical shifts to generate angle restraints. Both methods use the fact that the geometry around the alpha carbon affects the coupling constants and chemical shifts, so given the coupling constants or the chemical shifts, a qualified guess can be made about the torsion angles.
The progressive miniaturization of low-voltage lighting technology, such as LEDs and OLEDs, suitable to incorporate into low-thickness materials has fostered experimentation in combining light sources and wall covering surfaces for interior walls in the form of LED wallpaper.
Sources: en.wikipedia.org
==== Companion of the Order of St Michael and St George (CMG) ==== Jennifer Elizabeth Anderson, Director, Consular and Crisis, Foreign, Commonwealth and Development Office. For services to British Foreign Policy and to British Nationals Overseas. Zamir Nicholas Catasaras, Director General for Russia and Ukraine, Cabinet Office. For services to British Foreign Policy. Roger James Coventry, Criminal Justice Adviser. For services to Justice and Stability overseas. Colin Mark Evans, Director General, Foreign, Commonwealth and Development Office. For services to National Security. Dr Fiona Hill, Senior Fellow, Brookings Institution, Washington D.C., United States of America. For services to International Relations. Dr Rurik Miles Marsden, , Development Director, British Embassy Yangon, Myanmar. For services to International Development. Susanna Mary Davies Moorehead, lately Chair, Development Assistance Committee, The Organisation for Economic Co-operation and Development (OECD). For services to International Development and Diplomacy. Jane Anne Nelson, Director, Corporate Responsibility Initiative, Kennedy School of Government, Harvard University, United States of America. For services to Business and to Sustainability. Dr Sara Pantuliano, Chief Executive, ODI. For services to Peacebuilding, to Humanitarian Assistance and to International Development. Simon Penny, lately H.M. Trade Commissioner for the Middle East and Pakistan and H.M. Consul General to Dubai and the Northern Emirates. For services to International Trade and Investment.
== Sources == Rowland, Malcolm; Tozer, N. (2010). Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications (4 ed.). Philadelphia, PA: Lippincott Williams & Wilkins. ISBN 978-0-7817-5009-7. Welling, Peter G.; Tse, Francis L. S.; Dighe, Shrikant V. (1991). Pharmaceutical Bioequivalence. Drugs and the Pharmaceutical Sciences. Vol. 48. New York, NY: Marcel Dekker. ISBN 978-0-8247-8484-3. Hauschke, Dieter; Steinijans, Volker; Pigeot, Iris (2007). "Metrics to characterize concentration-time profiles in single- and multiple-dose bioequivalence studies". Bioequivalence Studies in Drug Development: Methods and Applications. Statistics in Practice. Chichester, UK: John Wiley and Sons. pp. 17–36. ISBN 978-0-470-09475-4. Retrieved 21 April 2011. Chow, Shein-Chung; Liu, Jen-pei (15 October 2008). Design and Analysis of Bioavailability and Bioequivalence Studies. Biostatistics Series. Vol. 27 (3rd ed.). FL: CRC Press. ISBN 978-1-58488-668-6.
The first investigation conducted in China was by the Wuhan Municipal Health Commission, responding to hospitals reporting cases of pneumonia of unknown etiology, resulting in the closure of the Huanan Seafood Wholesale Market on 1 January 2020 for sanitation and disinfection. The Chinese Center for Disease Control and Prevention (CCDC) entered the market the same day and took samples; as the animals had been removed before public-health authorities came in, no animals were sampled, although that would have been more conclusive. In April 2020, China imposed restrictions on publishing academic research on the novel coronavirus. Investigations into the origin of the virus would receive extra scrutiny and must be approved by Central Government officials. The restrictions do not ban research or publication, including with non-Chinese researchers; Ian Lipkin, a US scientist, has been working with a team of Chinese researchers under the auspices of the Chinese Center for Disease Control and Prevention, a Chinese government agency, to investigate the origin of the virus. Lipkin has long-standing relationships with Chinese officials, including premier Li Keqiang, because of his contributions to rapid testing for SARS in 2003. The Huanan live-animal market was suspected of being the source of the virus, as there was a major, early cluster of cases there. On 31 January 2021, a team of scientists led by the World Health Organization visited the market to investigate the origins of COVID-19.
The film received mixed reviews from critics, but DiCaprio's performance was praised and earned him the AACTA Award for Best Actor in a Leading Role. Critic Rafer Guzman of Newsday wrote that DiCaprio was not only "tough [...] but also vulnerable, touching, funny, a faker, a human. It's a tremendous, hard-won performance." Matt Zoller Seitz of Roger Ebert's website described his performance as "the movie's greatest and simplest special effect", and "iconic—maybe his career best". The film grossed $353 million worldwide, more than three times its budget. Three films were produced by DiCaprio under Appian Way in 2013—the ensemble crime thriller Runner Runner, which The Guardian's Xan Brooks described as "a lazy, trashy film that barely goes through the motions"; the commercially failed thriller Out of the Furnace; and the black comedy-drama The Wolf of Wall Street. DiCaprio reunited with Scorsese for the fifth time in The Wolf of the Wall Street, a film based on the life of stockbroker Jordan Belfort (played by DiCaprio), who was arrested in the late 1990s for securities fraud and money laundering. DiCaprio wanted to play Belfort ever since he had read his autobiography and won a bidding war with Warner Bros. against Brad Pitt and Paramount Pictures for the rights to Belfort's memoir in 2007. He was fond of Belfort's honest and unapologetic portrayal of his actual experiences in the book, and was inspired by the 2008 financial crisis to make the film. The Wolf of Wall Street received positive reviews for Scorsese's and DiCaprio's work together.
Sources: en.wikipedia.org
The two substrates of this enzyme are L-arogenic acid (shown as its conjugate base arogenate) and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are L-tyrosine, reduced NADH, and carbon dioxide. Nicotinamide adenine dinucleotide phosphate can be used as an alternative cofactor. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-CH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is L-arogenate:NAD(P)+ oxidoreductase (decarboxylating). Other names in common use include arogenic dehydrogenase (ambiguous), cyclohexadienyl dehydrogenase, and pretyrosine dehydrogenase (ambiguous).
===== Filamentous fungi ===== Filamentous fungi, especially Aspergillus and Trichoderma, have long been used to produce diverse industrial enzymes from their own genomes ("native", "homologous") and from recombinant DNA ("heterologous"). More recently, Myceliophthora thermophila C1 has been developed into an expression platform for screening and production of native and heterologous proteins.The expression system C1 shows a low viscosity morphology in submerged culture, enabling the use of complex growth and production media. C1 also does not "hyperglycosylate" heterologous proteins, as Aspergillus and Trichoderma tend to do.
=== Natural neurostimulation === In 2024, the theory of Natural Neurostimulation was introduced, opening the way to neurostimulation techniques which emulate, in neurological treatment, natural processes that appear during pregnancy. This notion was established by Prof Igor Val Danilov and his colleagues from Latvian universities. Latvian scientists claim that natural neurostimulation provides positive neuroplasticity, balancing the patient's nervous system in a case of systematic use of this sort of neurostimulation, emulating the natural process that causes mitochondrial and cognitive stress under similar environment. They provided evidence of the therapeutic effect of the complex impact of electromagnetic fields and acoustic waves, along with cognitive load, scaled based on the parameters of the physical interaction between mother and fetus.
The legendary religious zeal of the Normans was exercised in religious wars long before the First Crusade carved out a Norman principality in Antioch. They were major foreign combatants in the Reconquista in Iberia. In 1018, Roger de Tosny travelled to the Iberian Peninsula to carve out a state for himself from Moorish lands, but failed. In 1064, during the War of Barbastro, William of Montreuil, Roger Crispin and probably Walter Guiffard led an army under the papal banner which took a huge booty as they captured the city from its Andelusi rulers. Later a group of Normans led by a certain William (some have suggested this was William the Carpenter) participated in the failed siege of Tudela of 1087. In 1096, Crusaders passing by the siege of Amalfi were joined by Bohemond of Taranto and his nephew Tancred with an army of Italo-Normans. Bohemond was the de facto leader of the Crusade during its passage through Asia Minor. After the successful Siege of Antioch in 1097, Bohemond began carving out an independent principality around that city. Tancred was instrumental in the conquest of Jerusalem and he worked for the expansion of the Crusader kingdom in Transjordan and the region of Galilee.. After the First Crusade to the Levant, the Normans continued with their involvement in Iberia as well as other areas of the Mediterranean. Among them was Rotrou of Perche and his followers Robert Burdet and William Giffard who joined multiple expeditions into the Ebro Valley to aid Alfonso I of Aragon in his campaigns of conquest.
==== Mate choice ==== Mate choice is seen in cuttlefish species, where females prefer some males over others, though characteristics of the preferred males are unknown. A hypothesis states that females reject males by olfactory cues rather than visual cues. Several cephalopod species are polyandrous – accepting and storing multiple male spermatophores, which has been identified by DNA fingerprinting. Females are no longer receptive to mating attempts when holding their eggs in their arms. Females can store sperm in two places (1) the buccal cavity where recently mated males place their spermatophores, and (2) the internal sperm-storage receptacles where sperm packages from previous males are stored. Spermatophore storage results in sperm competition; which states that the female controls which mate fertilizes the eggs. In order to reduce this sort of competition, males develop agonistic behaviors like mate guarding and flushing. The Hapalochlaena lunulata, or the blue-ringed octopus, readily mates with both males and females.
Sources: en.wikipedia.org
The sequence is Met-Glu-His-Phe-Pro-Gly-Pro, a seven-residue peptide. The first four residues correspond to the ACTH(4-10) fragment, and Pro-Gly-Pro is added at the C-terminus. N-acetylated versions also appear in the literature and differ in mass.
Semax is a synthetic analog of the ACTH(4-10) fragment rather than a copy of the full hormone. Truncation plus the added tail removes the steroidogenic portion of ACTH. That distinction explains why it is studied for nervous-system effects instead of adrenal stimulation.
It is registered as a prescription product in Russia and has been used there clinically, chiefly by the intranasal route. No approval exists in the United States or the European Union. Availability elsewhere typically falls under research-chemical distribution, with varying purity documentation.
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.